SUSAN TOMPKINS: Open Payments
NPI 1245266881 · LUVERNE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$600 in 32 payments from 13 companies in 2025. Trend: 2023 $798 · 2024 $1,005 · 2025 $600
Food & beverage: $600
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $108 |
| ABBVIE INC. | 5 | $105 |
| GlaxoSmithKline, LLC. | 4 | $73 |
| Novo Nordisk Inc | 4 | $73 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Neurocrine BioSciences, Inc. | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
| Lundbeck LLC | 1 | $22 |
| Ardelyx, Inc. | 1 | $18 |
Products named: VRAYLAR, REXULTI, TRELEGY ELLIPTA, BREZTRI, Ozempic, INGREZZA, VOQUEZNA, XIFAXAN.
Industry payments across AL — which companies pay providers there.
